Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

HEART FAILURE

IMAGING

COMMUNITY CARDIOLOGY

EARLY CAREER INVOLVEMENT

354 - EVERYTHING A GENERAL CARDIOLOGIST NEEDS TO KNOW ABOUT CARDIOMYOPATHIES

Saturday, October 26, 2024
3:15 PM – 4:15 PM PT
Room: 211
Early Career Involvement
Workshop Description: Patients with cardiomyopathy are an important population at increased risk for adverse cardiac outcomes. Studies suggest that they comprise 11% of heart failure admissions, 33% of ICD implantations and 51% of heart transplantations. However, patients with cardiomyopathy are often faced with a lengthy diagnostic journey which can lead to delays in establishing the correct diagnosis and treatment. These observations highlight the need to improve education and awareness of this common and treatable cause of heart failure.
This is also an extremely timely topic with the recent publication of ESC practice guidelines on the management of cardiomyopathies in late 2023 and the development of a CCS clinical practice update on the contemporary management of hypertrophic cardiomyopathy due for release in late 2024.
In this workshop, the audience will learn tips and tricks for identifying these patients in their general practice. They will develop an evidence-based approach for using cardiac imaging to aid in the diagnosis and risk stratification of common cardiomyopathies. Finally, the audience will understand the role of specialized clinics in cascade testing and facilitating access to targeted therapies. The interactive format will keep the audience engaged and include live polling and a Q&A session with the panel at the end of the session.

Interactive and Engagement Activities Description: The welcome and introduction period will use audience polls to test general knowledge about cardiomyopathies.
There will be an 11-minute Question and Answer period at the end of the session where the audience will be invited to ask questions to the panel members (made up of the chair, co-chair and presenters).

Learning Objectives:

At the end of this session participants will be able to:
  • screen patients in their general practice with the potential for cardiomyopathies and propose an effective strategy for preliminary investigations;
  • identify appropriate cardiac imaging to aid the diagnosis and management of patients with cardiomyopathies and decipher the salient findings on imaging reports; and
  • recognize the importance of specialty clinics in improving care and outcomes for patients with cardiomyopathies.
Disclosure(s):
David Ian Paterson, MD, FRCPC: No financial relationships to disclose
Elizabeth A. Swiggum, MD, FRCPC, FCCS: BI Lilly Alliance: Advisory Board (Ongoing), Consulting Fees/Honoraria (Ongoing); Boehriger Ingelheim: Advisory Board (Ongoing), Consulting Fees/Honoraria (Ongoing), Multicentre tiral (Ongoing); Canadian Medical and Surgical Knowledge Translation Research Group: Speaker (Ongoing); Novartis: Advisory Board (Ongoing), Consulting Fees/Honoraria (Ongoing); NovoNordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Advisory Board (Ongoing), Amyloid clinic QI project funding (Ongoing)
Gavin Oudit, n/a: Sanofi: Research funding (Ongoing); Takeda: Research funding (Ongoing)
Gary R. Small, MB ChB PhD MRCP: No financial relationships to disclose
Joanne Joseph, MD: No financial relationships to disclose
Abhinav Sharma, MD, FRCPC: AREA19: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); AstraZeneca: Speaker fees (Ongoing); Boehringer Ingelheim: Speaker fees (Ongoing); Janssen: Speaker fees (Ongoing); Novartis: Speaker fees (Ongoing); Novo Nordisk: Speaker fees (Ongoing); Roche Diagnostics: Speaker fees (Ongoing); Servier: Speaker fees (Ongoing)